teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2648 News 


«12...1112131415161718192021...3233»
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
    [VIRTUAL] External validation of the MSBase model of individual treatment response (Crystal Ball 1.0) (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2456;    
    The previously developed models show excellent external validity. This validation of the original model in a non-overlapping cohort from the ME establishes generalizability of the Crystal Ball 1.0 model and exchangeability of its observations, which are critical for its application in practice.
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
    [VIRTUAL] External validation of the MSBase model of individual treatment response (Crystal Ball 1.0) (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2455;    
    The previously developed models show excellent external validity. This validation of the original model in a non-overlapping cohort from the ME establishes generalizability of the Crystal Ball 1.0 model and exchangeability of its observations, which are critical for its application in practice.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    [VIRTUAL] First-hand experience with ofatumumab at ASCLEPIOS study sites in Europe (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2449;    
    After gaining experience with ofatumumab within clinical trials, European neurologists consider ofatumumab a very efficient and safe treatment option. They rate the self-administered subcutaneous injection once a month as offering high convenience for patients and as facilitating processes at high-occupancy clinics and office-based practices.
  • ||||||||||  Ponvory (ponesimod) / J&J
    [VIRTUAL] Analysis and evaluation of ponesimod hepatic safety data (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2439;    
    Introduction: In the OPTIMUM Phase III study, the efficacy and safety of ponesimod 20 mg were compared to that of teriflunomide 14 mg. The pattern of hepatic effects observed with ponesimod treatment in the entire development program is consistent with the S1P class and no cautionary statement on adverse reactions for moderate and severe hepatic impairment categories was included in the label.
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
    [VIRTUAL] Treatment patterns in patients with multiple sclerosis: a single hospital cohort study in Sweden (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2434;    
    Most patients were treated with a DMT within months of diagnosis, with predominant initial use of interferons, and switching to more potent agents in later lines of therapy. Prescribing patterns are changing and expected to evolve further with earlier use of powerful agents.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    [VIRTUAL] Cladribine in a real world setting. The real patients (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2409;    
    23 patients switch from teriflunomide, 16 from dimethylfumarate, 14 from fingolimod, 22 from injectables, 1 from alemtuzumab... In the real world cladribine has proved to be effective, safe and very well tolerated.
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    [VIRTUAL] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2407;    
    In the real world cladribine has proved to be effective, safe and very well tolerated. Our findings suggests that dimethyl fumarate has a lower risk of discontinuation because of treatment failure among both treatment-experienced and treatment-naive patients.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Anti-Spike IgG after BNT162b2 vaccine in a group of multiple sclerosis patients from an exploratory case-control study in Italy (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2376;    
    In our study, most MS patients produce a serological response to BNT162b2 similar to non-MS controls; however, at-risk DMTs resulted in reduced anti-Spike levels and one ocrelizumab-treated patient did not respond. These observations should be better investigated and replicated in larger studies to support clinical decision in COVID-19 vaccine management.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    [VIRTUAL] Real-world experience with cladribine in the MSBase Registry (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2365;    
    The most common switches to cladribine are from other high-efficacy DMTs such as Natalizumab or Fingolimod. The annualised relapse rate on treatment is 0.11, consistent with clinical trial data.
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    [VIRTUAL] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2359;    
    Objective: To compare the clinical outcomes in patients on DMF and TFL in a real-world setting, where both drugs are licensed as a first-line disease modifying therapy (DMT) for RRMS... Analysis of real-world data showed that in RRMS, DMF treatment was associated with more favorable clinical outcomes compared to TFL.
  • ||||||||||  Mayzent (siponimod) / Novartis
    [VIRTUAL] Assessing the immune response to SARS-CoV-2 mRNA vaccines in patients with secondary progressive multiple sclerosis treated with siponimod (AMA-VACC clinical trial) (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2348;    
    Cohort 1 receives SARS-CoV-2 mRNA vaccination while continuing their current siponimod treatment, cohort 2 interrupts siponimod treatment for for the purpose of a full vaccination cycle and cohort 3 receives vaccination during continuous treatment with first-line DMTs (dimethylfumarate, glatirameracetate, interferons, teriflunomide) or no current treatment in clinical routine... This analysis will provide first data on the immune response after SARS-CoV-2 mRNA vaccination in patients with SPMS treated with siponimod and enable physicians to make an informed decision on the coordination of SARS-CoV-2 mRNA vaccination and SPMS treatment.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    [VIRTUAL] Assessing treatment response to oral drugs for multiple sclerosis in real world setting: a MAGNIMS study (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2335;    
    We retrospectively collected data of RRMS patients who started fingolimod (FNG), teriflunomide (TNF) or dimethyl fumarate (DMF) according to the following criteria: treatment-naive or switching from injectable DMTs; at least 1 year treatment duration; brain MRI scan collected at baseline and year 1; at least 3 years of clinical follow-up... We extend the results of previous studies, by demonstrating that early relapses and MRI activity in the first year of treatment are associated with an increased risk of short-term confirmed disability worsening and relapses in patients treated with oral DMTs.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] COVID-19 (inactivated and mRNA) vaccine and humoral response in people with multiple sclerosis: Chilean cohort (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2252;    
    In our cohort, most of the treatments are likely to produce humoral response to the COVID-19 vaccine, especially alemtuzumab, cladribine and natalizumab, regardless the infusion/administration time. Further study needs to be done that includes more patients with antiCD20 and fingolimod but also it is important that the studies take into consideration the type of vaccine (T cell dependent response), B cell reconstitution and lymphocyte subpopulations for B and T cells.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    [VIRTUAL] Effect of ofatumumab on brain volume loss vs historical placebo in relapsing multiple sclerosis (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2095;    
    In the phase 3 ASCLEPIOS I/II trials, ofatumumab 20 mg administered subcutaneously every 4 weeks (q4w) was superior to oral teriflunomide 14 mg once daily, with significant reduction in relapse rates, lesion numbers on MRI, neurofilament light levels greater delays in disability worsening in patients with RMS...MRI scans for RMS patients treated with placebo were collected at baseline, month 6, year 1 2 in the FREEDOMS and FREEDOMS II trials, a Phase 3 trials involving fingolimod... Based on our analysis using identical MRI methodology causal inference methods, ofatumumab significantly reduced disease related BVL when compared with placebo.
  • ||||||||||  teriflunomide / Generic mfg.
    [VIRTUAL] Impact of teriflunomide on innate immune cell activation in RRMS patients with limited signs of CNS pathology (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2059;    
    P=N/A, P4
    Innate immune cell activation was not altered during one year of teriflunomide treatment in any region of interest, and the patients remained clinically stable. However, due to the relatively mild nature of the cohort, and the initial low innate immune cell activation, the effect of teriflunomide on progression-promoting microglial activation remains unclear.
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
    [VIRTUAL] Evaluating DMT escalation based on isolated MRI activity (ePoster Library) -  Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1992;    
    Methods : From the Vienna Innsbruck MS database (VIMSD), we included RMS patients (18-65 years) with a) newly initiated moderately effective DMT (interferon-beta, glatiramer acetate, dimethyl fumarate, or teriflunomide) continued for 12 months, b) clinical stability (no relapses or disability progression) on DMT for 12 months, c) MRI at baseline (MRI-0) and after 12 months of DMT (MRI-1), and d) available clinical follow-up for ≥3 years... In our real-world cohort of clinically stable patients, DMT escalation based on isolated MRI activity only changed outcome when MRI activity fulfilled at least MAGNIMS criteria (exceeding 3 new/enlarged T2 lesions).